[Edaily Reporter Kim Kani] Bristol-Myers Squibb (BMY), a major U.S. global pharmaceutical and biotech healthcare company, is seeing its stock price rise after reporting second-quarter revenue and earnings that exceeded market expectations.
As of 3:13 p.m. on the 30th (local time), Bristol-Myers Squibb’s stock is trading at $65.11, up 3.19% from the previous day. Riding the momentum of an “earnings surprise” immediately after the market opened, the stock continues to climb by more than 3% in the afternoon session.
According to CNBC, this upward trend is the result of Bristol-Myers Squibb’s quarterly revenue and adjusted earnings per share (EPS) both exceeding market consensus.
Bristol-Myers Squibb reported second-quarter adjusted EPS of $2.04 and revenue of $12.97 billion, both exceeding Wall Street forecasts.
The company explained that strong sales of its core pharmaceutical products drove the “earnings surprise.”
As of 3:13 p.m. on the 30th (local time), Bristol-Myers Squibb’s stock is trading at $65.11, up 3.19% from the previous day. Riding the momentum of an “earnings surprise” immediately after the market opened, the stock continues to climb by more than 3% in the afternoon session.
According to CNBC, this upward trend is the result of Bristol-Myers Squibb’s quarterly revenue and adjusted earnings per share (EPS) both exceeding market consensus.
Bristol-Myers Squibb reported second-quarter adjusted EPS of $2.04 and revenue of $12.97 billion, both exceeding Wall Street forecasts.
The company explained that strong sales of its core pharmaceutical products drove the “earnings surprise.”
